renal outcomes. 4, 5 Despite normal baseline renal function, a single AKI episode increased the risk of chronic kidney disease (CKD) 1.9-13 times that of a matched non-AKI population, even after a short follow-up period. 6 Therefore, it is important to identify the drugs that are likely to induce AKI and lead to poor renal outcomes in clinical settings.
There is a growing consensus that a detailed evaluation of the information arising from pharmacovigilance activities is important to ensure the safe use of all drugs. 7, 8 Of note, pharmacovigilance practices can improve information feedback to medical staff and their patients in a timely manner, thereby reducing the overall risk of adverse effects to patients. Drugs are approved for clinical use after showing a satisfactory balance between benefits and risks. However, the safety profile of drugs can change over time as their use expands to patients with different characteristics. An increase in the number of patients exposed may also reveal rarer adverse effects. In Japan, the "Risk Management Plan Guidance,"
issued in 2012, 9 describes the basic ideas required for develop- Therefore, the objective of this study was to establish a comprehensive nationwide overview of drug-induced AKI based on a spontaneously reported adverse drug reactions database that was opened to the public by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.
| ME THODS
We used the Japanese Adverse Drug Event Report (JADER) database from the public release of PMDA as a large spontaneous reporting database, 11 containing data on adverse drug reactions After we removed duplicated data, the DEMO table was combined with REAC and DRUG tables using the ID number. In each case, the contribution of medications to adverse reactions was classified into three categories: "suspected medicine," "concomitant medicine," and "interaction." A "suspected medicine" was defined as a pharmaceutical product suspected of being associated with an ADR. When the reporter suspected an interaction, he/she reported it as an "interaction." A "concomitant medicine" was defined as another pharmaceutical product that had been used at the time of an ADR.
We only extracted cases that were classified as "suspected (ROR). The ROR is the number of reports of a specific adverse reaction caused by a drug divided by that of all other drugs in the database. In addition, it was frequently used with the spontaneous reporting database as a measure of the relative risk of drug-associated adverse events. A signal is considered to be present when the lower limit of the 95% confidence interval (CI) of the ROR is greater than one.
In this database, age, height, and weight data are presented in the form of age in decades, height in centimetre-denominated ranges, and weight in kilogram-denominated ranges. Because these data were not continuous variables, we could not use them to conduct multiple analyses. All analyses were performed with JMP Pro 12 (SAS Institute Inc., Cary, NC, USA).
| RE SULTS
In total, 5 195 890 reports were obtained after the combination of 
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| D ISCUSS I ON
In a large, nationwide study of recent pharmacovigilance data, we obtained a comprehensive overview of drugs inducing AKI. Of the 1 984 122 ADRs recorded in JADER during the study period, 12 964 (0.6%) corresponded to AKI. Our results revealed that the duration of drug exposure until the onset of AKI was most often within 1 month. Furthermore, we found that most AKI survivors showed recovery or remission after the index AKI episode.
In our analysis, it is noteworthy that many of the patients with AKI
were elderly (most frequently in their 70 s) and male. These results are consistent with reports that elderly and male patients could be more susceptible to insults and more likely to progress to AKI. 12, 13 Elderly patients often have multiple risk factors for AKI 14 because of concomitant diseases such as cardiovascular disease, CKD, diabetes, and heart failure; therefore, they have increased rates of exposure to diagnostic procedures and the administration of several nephrotoxic agents. As for the sex difference in AKI, experimental studies demonstrated that ischaemia-reperfusion injury led to less of a reduction in the renal function and less evidence of tissue damage in female mice. 15 This lower-level susceptibility to ischaemic insults of the kidney in female patients was also noted in rat models of ischaemic injury to the heart 16 and brain. 17 We used ROR, a sensitive and quantitative method based on the disproportional reporting rate, to identify drug-related risk of a particular ADR. Our results revealed that the drug classes most frequently associated with AKI were antivirals and antibacterial agents for systemic use. Among the antivirals, valaciclovir was associated with the highest rate of AKI. This is consistent with some case reports. 18, 19 However, one retrospective population-based cohort study revealed that valacyclovir (or oral acyclovir) was not associated with a higher risk of AKI compared with famciclovir (an antiviral drug with no known renal toxicity) in elderly patients. 20 This inconsistency is partly due to the differences in subjects (new outpatients) and prescription duration (average of 7 days) in their study. Furthermore, our data also included long-term and repeat users of valaciclovir. Thus, repeat users warrant careful observation. As for antibacterial agents, piperacillin-tazobactam and vancomycin were frequently reported to be associated with AKI. Piperacillin-tazobactam alone has rarely been F i g u r e 1 . Flow chart for the construction of data analysis tables. We removed duplicated data from the DRUG and REAC tables. 25 The DEMO table was combined with the DRUG and REAC tables using the ID number for each table. This table was used as an "all data table" in which the causes of medication-related adverse reactions were classified into three categories: "suspected medicine," "concomitant medicine," and "interaction." We extracted the cases classified as "suspected medicine" and created a "suspected medicine data reported to be associated with AKI, 21 whereas the association of vancomycin alone with AKI has been reported. 22, 23 However, vancomycin in combination with piperacillin-tazobactam was associated with a greater risk of AKI than vancomycin with or without β-lactam. 24 Clinically, the combination of piperacillin-tazobactam and vancomycin is often used, and so it is noteworthy that their combined use increased the risk.
The remaining drugs were associated with higher rates of 
| WHAT IS NE W AND CON CLUS I ON
The rank-order of the suspected drugs associated with AKI was determined using a nationwide pharmacovigilance database. The data strongly suggest that physicians should take precautions on using drugs that induce AKI and should select appropriate therapeutic medicines to avoid potential AKI.
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